Tesamorelin before and after at 1 month One month is early
Adverse event rates were similar between antibody-positive and antibody-negative patients, with the exception of injection site reactions
Two people who start at the same point may never reach the same later stage, since the pace and ceiling of any plan depend on individual response rather than a shared target
The studied dosing starts low (about 2 mg weekly) and is increased roughly every four weeks to a target dose, with 12 mg being the highest dose in the main Phase 2 obesity trial
Additionally, compared to glimepiride, a commonly used sulfonylurea, exenatide was able to significantly reduce cardiovascular risk factors such as body mass index, blood pressure, and high-density lipoprotein (HDL)
Back Knudsen, B, Lau, J (12 April 2019) 'The discovery and development of Liraglutide and Semaglutide', Frontiers in Endocrinology